Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023.

{"article_title":"Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023.","author":"Stephenson A, Bass EB, Bixler BR, Daneshmand S, Kirkby E, Marianes A, Pierorazio PM, Sharma R, Spiess PE","journal_title":"The Journal of urology","issn":"1527-3792","isbn":"","publication_date":"2024-01-01","volume":"211","issue":"1","first_page":"20","page_count":"","accession_number":"37707243","doi":"10.1097\/JU.0000000000003694","publisher":"Wolters Kluwer","doctype":"Journal Article","subjects":"United States; Testicular Neoplasms diagnosis; Testicular Neoplasms therapy; Humans; Male; United States","interest_area":["Oncology"," Obstetrics & Gynecology"],"abstract":"Purpose: The purpose of this American Urological Association (AUA) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for early-stage testicular cancer. Methodology\/methods: The original methodology protocol included searches of PubMed\u00ae, Embase\u00ae, and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 1980 through August 2018. The search strategy used medical subject heading (MeSH) terms and key words relevant to the diagnosis and treatment of early-stage testicular cancer. The searches conducted for the update presented herein utilized the same methodological protocol to capture literature published through March 2023. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions. Results: Updates were made to statements on imaging, seminoma management, non-seminoma management, surveillance for stage I testicular cancer, and additional survivorship. Further revisions were made to the methodology and reference sections as appropriate. Conclusions: This guideline seeks to improve clinicians' ability to evaluate and treat patients with early-stage testicular cancer based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=37707243","isPdfLink":false,"isSAML":true,"an":"37707243","number_other":"","type_pub":"","issn_electronic":"1527-3792","languages":"English","language":"eng","date_entry":"Date Created: 20230914 Date Completed: 20231227 Latest Revision: 20231227","date_update":"20231228","titleSource":"The Journal of urology [J Urol] 2024 Jan; Vol. 211 (1), pp. 20-25. Date of Electronic Publication: 2023 Sep 14.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2024-01-01","description":"Purpose: The purpose of this American Urological Association (AUA) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for early-stage testicular cancer.<br \/>Methodology\/methods: The original methodology protocol included searches of PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 1980 through August 2018. The search strategy used medical subject heading (MeSH) terms and key words relevant to the diagnosis and treatment of early-stage testicular cancer. The searches conducted for the update presented herein utilized the same methodological protocol to capture literature published through March 2023. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions.<br \/>Results: Updates were made to statements on imaging, seminoma management, non-seminoma management, surveillance for stage I testicular cancer, and additional survivorship. Further revisions were made to the methodology and reference sections as appropriate.<br \/>Conclusions: This guideline seeks to improve clinicians' ability to evaluate and treat patients with early-stage testicular cancer based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.","upload_link":"https:\/\/dx.doi.org\/doi:10.1097\/JU.0000000000003694","no_of_pages":"","authored_by":"Stephenson A, Bass EB, Bixler BR, Daneshmand S, Kirkby E, Marianes A, Pierorazio PM, Sharma R, Spiess PE","additionalInfo":{"Authored_By":"Stephenson A, Bass EB, Bixler BR, Daneshmand S, Kirkby E, Marianes A, Pierorazio PM, Sharma R, Spiess PE","Journal_Info":"Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline","Published_Date":"2024-01-01","Source":"The Journal of urology [J Urol] 2024 Jan; Vol. 211 (1), pp. 20-25. Date of Electronic Publication: 2023 Sep 14.","Languages":"English","Electronic_ISSN":"1527-3792","MeSH_Terms":"Testicular Neoplasms*\/diagnosis , Testicular Neoplasms*\/therapy, Humans ; Male ; United States","Subjects":"Humans, Male, United States, Testicular Neoplasms diagnosis, Testicular Neoplasms therapy","Title_Abbreviations":"The Journal of urology","Volume":"211"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"37707243","RelevancyScore":"874","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"874.100524902344"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=37707243&authtype=shib&custid=ns346513&group=main&profile=eds"}